Press release
Advantages of single-use bioreactors market and Future innovations
Single-use bioprocessing systems is a significant part of biopharmaceutical development and production processes. These systems have made the production of clinical test materials cost-effective and flexible. The market for single-use bioprocessing systems is expected to grow at a double-digit, and in two-third of the bio processes this single-use bioprocessing systems are used. It is used in a broad range of techniques in cases of biopharmaceutical purification, mixing, filtration, upstream expression, storage, and separations. The technology aims on the development of disposable accessories and bio-processing equipment to manufacture biopharmaceutical product.With the rising adoption and acceptance of single-use bioprocessing systems in upstream commercial (GMP) product manufacture, currently there is rising growth of upstream market. High market growth is expected in the next five to seven years as it is integrated to commercial-scale/GMP single-use systems. There are many advantages associated with the usage of single-use bioprocess system disposal options, such as negligible or very low operating cost, advantage of recycling of the device, and reduces risk of cross-contamination. Compared to stainless steel, they are faster to implement, and cost-effective. The initial cost of investment is also comparatively lower. The systems are comparatively environmental compatible. But there are some challenges associated with the system. As, the high cell density and product titers, the classical process is far superior process. The safety of the commercial market is the primary concern of the manufacturers. There are regulatory obstacles involved in plastic safety. There are also stability and other inflexibility issues, and to overcome it latest technological advancements have been made by different companies which would provide flexibility of the system. Moreover, supply chain can be a major challenge involving polymer manufacturers and downstream formulators.
The single use bioprocessing systems market can be segmented on the basis of application. The segment can be categorized into research and development (R&D) support single use systems and GMP/commercial single use systems. R&D support single use systems comprises containers, tubing, sampling systems, connectors, mixers, disposable bioreactors, purification devices and columns and probes and sensors. GMP single use systems comprise manifolds, tubing storage containers and disposable used in stainless steel based bioreactors. Of these two segments research and development accounts for the majority share of the market the commercial and GMP segment occupied almost one-fourth of the market share.
Download Free exclusive Sample of this report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3753
Geographically, the single-use bioprocessing systems market can be segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). North America holds the leading position in the single-use bioprocessing systems market followed by Europe. Asia Pacific is the most promising market for single-use bioprocessing systems market due to various emerging economies. Growing demand for the use of biodisposables in the manufacture of vaccines, monoclonal and other biopharmaceuticals is a major factor that is expected to drive the market in the regions. There is intense market rivalry observed for single use bioprocessing systems. The major players operating in this market include Sartorius Stedim Biotech S.A., Thermo Fisher Scientific, Merck KGaA, GE Healthcare, while the other prominent vendors includes Eppendorf AG, Broadley-James Ltd., Parker Hannifin Corporation, Saint-Gobain Corporation, STI Components Inc., Tarpon Biosystems Inc., Cellexus Ltd., Pall Corporation and others. Among all the players ThermoFisher Scientific occupies the largest share of the market. These players dominate the market due to innovative and highly effective products.
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
90 State Street, Suite 700 Albany, NY 12207
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advantages of single-use bioreactors market and Future innovations here
News-ID: 351104 • Views: …
More Releases for GMP
Creative Peptides Released GMP Synthesis Service
Located in Shirley, New York, the world’s leading peptide supplier Creative Peptides announced the launch of its GMP synthesis (https://www.creative-peptides.com/services/custom-gmp-peptide-synthesis-services.html ) business on August 29, 2018. Now this company is focused on the development and GMP manufacturing of pharmaceutical grade peptides.
As the demand of pharmaceutical market continues to grow, more and more pharmas and research institutions choose the CMO and CRO models to expand their businesses, which is more…
Diapharm implements European GMP guidelines in China
Münster (DE), London (UK), Ningbo (CN), 20 December 2013 – Pharmaceutical service provider Diapharm (diapharm.com) is increasing its business activities in China: Diapharm has now implemented a “European” quality management system for Neptune Pharma Ltd (www.neptunepharma.com) in their Joint Venture Partner’s factory in Ningbo, Zhejiang Province. And it has done so successfully: The veterinary medicinal product Trident 500mg/g Powder for Suspension for Fish Treatment (www.trident-50.com), is manufactured onsite under EU…
ECA Foundation releases free GMP WebApp
The ECA Foundation has been providing advanced training and information services in the pharmaceutical industry and especially with regard to pharmaceutical Quality Assurance and GMP compliance for more than 10 years. Now the organisation took advantage of its extensive experience to develop a further free of charge service – the new GMP WebApp.
This new GMP WebApp runs on all smartphones and tablet PCs (Apple and Android platforms) and allows users…
GMP Friction Products Awarded ISO 9001:2008
Internationally Recognized Certification Measures Consistency in Process, Procedure and Quality Performance in Manufacture of Friction Materials
AKRON, OH (March 23, 2011) -- GMP Friction Products, a world leader manufacturing powdered metal friction products for clutch plates and brake pads, recently received certification for ISO 9001:2008.
“ISO 9001:2008 signifies we have taken the extra measure of documenting the policies and standards to ensure consistent compliance with our manufacturing processes,” said Jerry Lynch,…
GMP MANUAL Volume 2 - Validation Procedures by Maas & Peither AG – GMP Publish …
GMP Publishing is launching its new GMP MANUAL Volume 2 – Validation Procedures.
The compendium on validation procedures was written by Dr. Doris Borchert, Dr. Peter Bosshard, Dr. Ralph Gomez, Dr. Michael Hiob, Dr. Christine Oechslein, Max Lazar, Ulrike Reuter, Michael Schulte, Uwe Schwarzat – all international experts and key opinion leaders. They share their detailed understanding of the various aspects of the validation process in clear and comprehensive style…
blue inspection body celebrates 50 GMP audits
Münster (Germany), 20 November 2009. Two years after founding the company and just 18 months after gaining the accreditation blue inspection body GmbH announced today the successful execution of its 50th GMP audit. Further audit trips to China, India, Israel and various European countries have been scheduled already, meaning that in the first quarter 2010 the 75th audit is targeted to be completed. Blue, as a privately organised inspection body,…